Spyre's SPY072 basket trial heads toward three-indication readout in Q4 2026
SKYWAY will test the anti-TL1A antibody head-on against DAS-CRP, ACR20 and ASDAS bars across RA, PsA and axial spondyloarthritis with no direct same-target rival yet in human data.
Executive Summary
- Spyre Therapeutics is heading toward a multi-indication proof-of-concept readout for its anti-TL1A antibody in three separate rheumatic diseases, each carrying its own disease-specific primary endpoint.
- The trial extends a target mechanism already advancing in inflammatory bowel disease into a new therapeutic area, with no other anti-TL1A program in human testing across these same indications yet.
- Enrollment closed at its planned target with no growth or shortfall, and the trial has held a stable primary completion date since a single schedule reset in September 2025, arguing that execution is not the open question here.
- The result will need to clear separate, validated efficacy bars in each indication for the readout to inform Spyre's stated plan to enter late-stage development in 2027.
The trial
SKYWAY (NCT07148414), registered as SKYWAY-RD, is a randomized, placebo-controlled Phase 2 study of SPY072 enrolling adults with moderate-to-severely active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who had an inadequate response to prior conventional or biologic therapy. The trial carries disease-specific primary endpoints: change in DAS-CRP for rheumatoid arthritis, change in ASDAS for axial spondyloarthritis, and ACR20 response for psoriatic arthritis. Spyre said in a January 12, 2026 release that SKYWAY enrollment was on track and that all three indications were expected to read out in the fourth quarter of 2026. NCT07148414+1A Study of SPY072 in Rheumatic DiseaseNCT07148414Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts ...Jan 12, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Where the trial stands
The trial enrolled to its 285-patient target with no enrollment growth or shortfall recorded, a change the operational model classifies as typical and not a signal of trouble. The registry shows the primary completion date was reset once, from March 27, 2028 to October 31, 2026, in September 2025, and has not moved since. The trial's status shifted from Recruiting to Active, not recruiting on June 5, 2026, consistent with enrollment having closed at its planned end. Spyre's sponsor guidance for the Q4 2026 readout window has repeated unchanged across more than twenty disclosures between January and June 2026, without a single revision to the stated quarter. NCT07148414+1A Study of SPY072 in Rheumatic DiseaseNCT07148414Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts ...Jan 12, 2026
The competitive frame
No industry-sponsored trial in the current field shares both the anti-TL1A target and rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis as its indication; the nearest anti-TL1A programs, including Roche's afimkibart and Merck's tulisokibart, are running in Crohn's disease and ulcerative colitis, not rheumatic disease. The competitors that do share SKYWAY's indications, including AbbVie's risankizumab, Takeda's zasocitinib, and Janssen's guselkumab, work through IL-23 or JAK1 rather than TL1A, so they are contextual neighbors on indication only, not mechanism. SKYWAY will be the first trial to generate human efficacy data for an anti-TL1A antibody in RA, PsA, or axSpA, positioned against a rheumatic-disease field where no validated TL1A-driven mechanism yet exists in these specific settings.
What the readout can establish
The randomized, placebo-controlled design lets SKYWAY produce a decision-grade signal on whether SPY072 separates from placebo on each indication's own accepted efficacy measure, DAS-CRP, ASDAS, or ACR20, rather than only a directional trend. Because the trial is not registrational, the result will function as proof-of-concept evidence to inform whether Spyre proceeds into the late-stage program it has said it plans to start in 2027, rather than as a standalone basis for regulatory filing. NCT07148414+1A Study of SPY072 in Rheumatic DiseaseNCT07148414Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts ...Jan 12, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.